Activity of CP 99,219 Compared with Those of Ciprofloxacin, Grepafloxacin, Metronidazole, Cefoxitin, Piperacillin, and Piperacillin-tazobactam Against 489 Anaerobes

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 1994 Oct 1

PMID 7840591

Citations 37

Authors

S K Spangler

M R Jacobs

P C Appelbaum

Affiliations

Soon will be listed here.

Abstract

Agar dilution was used to compare the in vitro activity of CP 99,219 with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes. CP 99,219 yielded a MIC for 50% of the strains tested (MIC50) of 0.25 micrograms/ml and a MIC90 of 1.0 microgram/ml, with 99.6% of the strains susceptible at a breakpoint of 2.0 micrograms/ml. Ciprofloxacin and grepafloxacin were less active (MIC50, 4.0 micrograms/ml; MIC90, 32.0 micrograms/ml and 2.0 and 16.0 micrograms/ml, respectively). Metronidazole was active against all gram-negative rods (MIC90, 4.0 micrograms/ml), but 31% of the gram-positive anaerobes were resistant at > 8.0 micrograms/ml. Cefoxitin was active against 84% of all strains at < or = 16.0 micrograms/ml, with a MIC50 of 4.0 micrograms/ml and a MIC90 of 32.0 micrograms/ml. Tazobactam enhanced the activity of piperacillin against > 95% of the beta-lactamase-producing gram-negative anaerobic rods (MIC90, 16.0 micrograms/ml).

Citing Articles

Control of Clostridium difficile-associated diarrhea by antibiotic stewardship in a small community hospital.

Schabas A, Fisman D, Schabas R Can J Infect Dis Med Microbiol. 2013; 23(2):82-3.

PMID: 23730314 PMC: 3403666. DOI: 10.1155/2012/358059.

The new fluoroquinolones: A critical review.

Zhanel G, Walkty A, Vercaigne L, Karlowsky J, Embil J, Gin A Can J Infect Dis. 2012; 10(3):207-38.

PMID: 22346384 PMC: 3250697. DOI: 10.1155/1999/378394.

Trovafloxacin enhances the inflammatory response to a Gram-negative or a Gram-positive bacterial stimulus, resulting in neutrophil-dependent liver injury in mice.

Shaw P, Ganey P, Roth R J Pharmacol Exp Ther. 2009; 330(1):72-8.

PMID: 19351866 PMC: 2700160. DOI: 10.1124/jpet.109.151068.

Antianaerobic activity of a novel fluoroquinolone, WCK 771, compared to those of nine other agents.

Peric M, Jacobs M, Appelbaum P Antimicrob Agents Chemother. 2004; 48(8):3188-92.

PMID: 15273148 PMC: 478502. DOI: 10.1128/AAC.48.8.3188-3192.2004.

In vitro activities of a new des-fluoro(6) quinolone, garenoxacin, against clinical anaerobic bacteria.

Liebetrau A, Rodloff A, Behra-Miellet J, Dubreuil L Antimicrob Agents Chemother. 2003; 47(11):3667-71.

PMID: 14576144 PMC: 253765. DOI: 10.1128/AAC.47.11.3667-3671.2003.

References

Appelbaum P, Spangler S, Jacobs M . Evaluation of two methods for rapid testing for beta-lactamase production in Bacteroides and Fusobacterium. Eur J Clin Microbiol Infect Dis. 1990; 9(1):47-50. DOI: 10.1007/BF01969535. View

Appelbaum P, Spangler S, Jacobs M . Beta-lactamase production and susceptibilities to amoxicillin, amoxicillin-clavulanate, ticarcillin, ticarcillin-clavulanate, cefoxitin, imipenem, and metronidazole of 320 non-Bacteroides fragilis Bacteroides isolates and 129 fusobacteria from 28.... Antimicrob Agents Chemother. 1990; 34(8):1546-50. PMC: 171870. DOI: 10.1128/AAC.34.8.1546. View

Appelbaum P, Philippon A, Jacobs M, Spangler S, Gutmann L . Characterization of beta-lactamases from non-Bacteroides fragilis group Bacteroides spp. belonging to seven species and their role in beta-lactam resistance. Antimicrob Agents Chemother. 1990; 34(11):2169-76. PMC: 172019. DOI: 10.1128/AAC.34.11.2169. View

Barry A, Fuchs P . In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin. Antimicrob Agents Chemother. 1991; 35(5):955-60. PMC: 245135. DOI: 10.1128/AAC.35.5.955. View

Goldstein E, Citron D . Comparative activity of ciprofloxacin, ofloxacin, sparfloxacin, temafloxacin, CI-960, CI-990, and WIN 57273 against anaerobic bacteria. Antimicrob Agents Chemother. 1992; 36(5):1158-62. PMC: 188857. DOI: 10.1128/AAC.36.5.1158. View

Appelbaum P, Spangler S, Pankuch G, Philippon A, Jacobs M, Shiman R . Characterization of a beta-lactamase from Clostridium clostridioforme. J Antimicrob Chemother. 1994; 33(1):33-40. DOI: 10.1093/jac/33.1.33. View

Gooding B, Jones R . In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone. Antimicrob Agents Chemother. 1993; 37(2):349-53. PMC: 187667. DOI: 10.1128/AAC.37.2.349. View

Eliopoulos G, Klimm K, Eliopoulos C, Ferraro M, Moellering Jr R . In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria. Antimicrob Agents Chemother. 1993; 37(2):366-70. PMC: 187672. DOI: 10.1128/AAC.37.2.366. View

Bauernfeind A . Comparative in-vitro activities of the new quinolone, Bay y 3118, and ciprofloxacin, sparfloxacin, tosufloxacin, CI-960 and CI-990. J Antimicrob Chemother. 1993; 31(4):505-22. DOI: 10.1093/jac/31.4.505. View

10.

Barry A, Fuchs P, Citron D, Allen S, Wexler H . Methods for testing the susceptibility of anaerobic bacteria to two fluoroquinolone compounds, PD 131628 and clinafloxacin. J Antimicrob Chemother. 1993; 31(6):893-900. DOI: 10.1093/jac/31.6.893. View

11.

Appelbaum P, Spangler S, Jacobs M . Susceptibility of 539 gram-positive and gram-negative anaerobes to new agents, including RP59500, biapenem, trospectomycin and piperacillin/tazobactam. J Antimicrob Chemother. 1993; 32(2):223-31. DOI: 10.1093/jac/32.2.223. View

12.

Jones R, Erwin M . In vitro activity of CP-74667 compared with four other fluoroquinolones. Diagn Microbiol Infect Dis. 1992; 15(6):531-6. DOI: 10.1016/0732-8893(92)90104-2. View